EFFECTS OF EZETIMIBE ON ABSORPTION OF DIETARY FATTY ACIDS-GCRC PILOT STUDY

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 依折麦布是FDA批准的用于治疗高胆固醇血症的药物，其通过抑制胆固醇的肠道吸收起作用。然而，最近在小鼠中进行的一项研究表明，依折麦布还可显著降低膳食饱和脂肪酸的吸收，从而对饮食诱导的肥胖产生抵抗力。 在这项初步研究中，我们将使用无创蔗糖聚山嵛酸酯方法测量健康受试者在依折麦布治疗1个月前后对单个膳食脂肪酸的肠道吸收。DNA也将被收集和储存，用于未来分析遗传对脂肪酸吸收的影响。 我们假设依折麦布将减少人体对饱和脂肪酸的吸收，如果是这样的话，最终可能在预防肥胖和2型糖尿病中发挥作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ezetimibe is an FDA approved drug for the treatment of hypercholesterolemia, which acts by inhibiting the intestinal absorption of cholesterol. However, a recent study in mice has shown that ezetimibe also significantly reduces the absorption of dietary saturated fatty acids, thereby conferring resistance to diet-induced obesity. In this pilot study we will use the non-invasive sucrose polybehenate method to measure the intestinal absorption of individual dietary fatty acids in healthy subjects before and after one month of treatment with ezetimibe. DNA will also be collected and stored for future analysis of genetic effects on fatty acid absorption. We hypothesize that ezetimibe will reduce the absoption of saturated fatty acids in humans, and if so, could ultimately have a role in the prevention of obesity and type 2 diabetes.